Hello Sir,

Hope you are doing well.

Recently, I came across Mitsu Chem Plast Ltd.

The company makes plastic industrial packaging products and hospital furniture parts.

What I found interesting about the company is the way it has grown over the years – From Rs 60 crore sales in FY 13 to Rs 309 crore in FY 23 and similarly Rs 2 crore PAT in FY 13 to Rs 12 crore in FY 23.

The last 4-5 quarters have been subdued for the company on account of fall in commodity prices and relatively low demand. The management is expecting improvement in sales and profitability in H2 FY 24.

Below, we have shared interesting insights from the Q2 FY 24 con-call of Mitsu Chem Plast to understand the current situation and the outlook for the company.


Before that, if you ever find a good stock in an ignored sector with promoter buying from market and increasing his stake, you should sit up and study the company in greater detail…something good might be brewing.

We recently released our new stock recommendation for Alpha/Alpha + members based on the same framework – for details click HERE


Mitsu Chem Plast – Insights from Q2 FY 24 con-call of the company

– Basic details

  • We ended quarter Q2 FY 24 with a total income of Rs 76.01 Crores. Despite cost pressure we reported EBITDA of Rs 5.42 Crores. Net profit came at Rs 1.50 Crores
  • The companies molded industrial plastic packaging products accounted for 87.5% of the sales as it continues to supply to various industries such as chemical, pharmaceutical, dye, agrochemical, disinfectant, etc.
  • The hospital furniture parts vertical contributed 9% and other vertical contributed 3.5% to the total revenue
  • Q2 volume – It is approximately 4460 metric tonnes…last year it was around 3,400 tonnes
  • We are optimistic on demand growth while we continue to focus on cost optimization and profitability improvement
  • On the demand side, the plastic packaging demand is robust and with the rising demand from petrochemical, pharmaceutical, chemicals and agrochemicals, the outlook is optimistic
  • Last quarter we have added around four to five new customers and we are trying even in this quarter also

– Rights issue

  • We are planning to raise funds up to the tune of approximately Rs 45 Crores

– Capacity utilization

  • The company’s plant operated at an average capacity utilization of around 70% on installed capacity of 25,000 plus metric tonnes per annum
  • Basically we can reach up to 85% or maybe till 87% to 88%

– International markets

  • It is a little difficult to enter there and hence what we are trying to do from last two years is we are taking many exhibitions
  • We are trying to build repo with customers and the sampling and everything else

– Raw material prices

  • It looks like this must be a bottom or maybe some $50 to $60 may go down for the prices
  • Further if the demand comes in chemical and pharmaceutical sector, the polymer prices also may increase at least $50 to $100

– Guidance

  • I think the first half was very, very average and it was not really good. Even Q2 also was almost similar but here I can see a robust growth in Q3 and Q4
  • I think if the demand comes yes we are ready with all the infrastructure so maybe we can go up to 85% utilization
  • I think the second half should be more than 10% margin in EBITDA so that should be our target
  • last year is exceptional but most of the year we have seen 20% to 30% to 35% growth and that is what we intend to achieve for coming two to three years



Disclaimer: This is not a recommendation to buy/sell Mitsu Chem Plast. The securities quoted are for illustration only and are not recommendatory.


Best Regards,

Ekansh Mittal
Research Analyst
Web: https://www.katalystwealth.com/


SEBI Research Analyst Registration No. INH100001690
Research Analyst Details

Name: Ekansh Mittal     Email Id: [email protected]    Ph: +91 727 5050062

Details of Associate: Not Applicable

Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.

Disclaimer: http://www.katalystwealth.com (here in referred to as Katalyst Wealth) is the domain owned by Ekansh Mittal. Mr. Ekansh Mittal is the sole proprietor of Mittal Consulting and offers independent equity research services to investors on subscription basis. SEBI (Research Analyst) Regulations 2014, Registration No. INH100001690

Address – 7, Panch Ratan, 7/128, Swaroop Nagar, Kanpur – 208002, Contact No. – +91-7275050062

Compliance Officer – Mr. Ekansh Mittal, +91-9818866676, ekansh@katalystwealth.com

Grievance Redressal – Mittal Consulting, grievances@katalystwealth.com, +91-9818866676, +91-7275050062

“Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors”.

“Investment in securities market are subject to market risks. Read all the related documents carefully before investing.”

The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Ekansh Mittal/Mittal Consulting/Katalyst Wealth is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Ekansh Mittal or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Ekansh Mittal, nor its employees, agents nor representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Ekansh Mittal/Mittal Consulting or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.

The recipients of this report should rely on their own investigations. Ekansh Mittal/Mittal Consulting and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Mittal Consulting has incorporated adequate disclosures in this document. This should, however, not be treated as endorsement of the views expressed in the report.

We submit that no material disciplinary action has been taken on Ekansh Mittal by any regulatory authority impacting Equity Research Analysis.

Disclaimer: You can access it here – LINK

Whether the research analyst or research entity or his associate or his relative has any financial interest in the subject company/companies and the nature of such financial interest – No

Whether the research analyst or research entity or his associates or his relatives have actual/beneficial ownership of 1% or more securities of the subject company (at the end of the month immediately preceding the date of publication of the research report or date of the public appearance) – No

Whether the research analyst or research entity or his associate or his relative has any other material conflict of interest at the time of publication of the research report or at the time of public appearance – No

Whether it or its associates have received any compensation from the subject company in the past twelve months – No

Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past 12 months – No

Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No

Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No

Whether the subject company is or was a client during twelve months preceding the date of distribution of the research report and the types of services provided – No

Whether the research analyst has served as an officer, director or employee of the subject company – No

Whether the research analyst or research entity has been engaged in market making activity for the subject company – No